MEDIAN Technologies Announces New €568,000 Project Award
MEDIAN Technologies confirms its commercial dynamics with a newly awarded project for image management in a phase II clinical trial for lung cancer.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced it has been selected to provide imaging solutions and services in a phase II clinical trial for non-small cell lung cancer. This trial is sponsored by a global biopharmaceutical company.
As part of the project, imaging data would be acquired in clinical sites based in three Asian countries: China, Korea and Taiwan. Anticipated total enrollment would be 200 patients with a forecasted clinical trial start in 2015.
Within the framework of the study, MEDIAN would provide a set of imaging services, enabling imaging data collection and quality control. Furthermore, MEDIAN would manage the image independent reviews performed by radiologists using the MEDIAN LMS platform.
The project, awarded through MEDIAN alliance with its strategic partner, would represent a contract of €568,000 (eq. $755,000) for MEDIAN.
Since the beginning of 2013, MEDIAN Technologies has recorded €3.7M (eq. $4.9M) of orders, including €0.8M of firm orders and €2.9M of project awards*.
“We are very proud of this new success with one of the leading pharmaceutical companies worldwide. This project clearly demonstrates the relevance of our strategic partnerships, which enable us to have a global reach” said MEDIAN’s Chief Executive Officer, Fredrik Brag.
[*] A project award is a notification announcing that the solution provided the company has been selected for the project. A binding contract should be signed within the 18 months following the award.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”